Related Experiment Video
Updated: Mar 26, 2026
09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
12.2K
Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression
Maria Albanese1,2, Sara Zagaglia1,3, Doriana Landi1,2
1Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University, Via Montpellier 1, 00133, Rome, Italy.
Journal of Neuroinflammation
|February 12, 2016
Summary
Elevated cerebrospinal fluid lactate in multiple sclerosis (MS) patients predicts greater disease severity and neuroaxonal damage, offering a potential early biomarker for relapsing-remitting MS (RRMS). This finding highlights metabolic pathway alterations in MS progression.
Area of Science:
- Neuroscience
- Biochemistry
- Clinical Neurology
Background:
- Altered cerebrospinal fluid (CSF) lactate levels are linked to neurodegenerative diseases and mitochondrial dysfunction.
- Investigated the association between CSF lactate, disease severity, and neuroaxonal damage markers in multiple sclerosis (MS).
Purpose of the Study:
- To explore the relationship between CSF lactate levels and clinical measures of disease severity and progression in MS patients.
- To determine if CSF lactate correlates with biomarkers of neuroaxonal damage in MS.
Main Methods:
- Included 118 relapsing-remitting MS (RRMS) patients and 157 controls.
- Measured CSF lactate, tau protein, and neurofilament light at diagnosis.
- Assessed clinical severity (PI, MSSS, BREMS) and followed patients for 5 years.
Main Results:
- RRMS patients exhibited higher CSF lactate than controls.
- CSF lactate positively correlated with disease severity scores (PI, MSSS, BREMS) and neurofilament light and tau protein levels.
- A negative correlation was observed between CSF lactate and disease duration.
Conclusions:
- CSF lactate may serve as an early predictor of RRMS disease severity, alongside other tissue damage biomarkers.
- Understanding altered mitochondrial metabolism in RRMS could lead to new therapeutic targets for axonal damage.
